Binding Letter of Intent to replace existing $53m facility

• Nexalis signs LOI with Point8 Capital for a new $53m funding facility
• Facility supports key clinical programs for Breakthrough Cancer Pain, Panic Disorder, and Treatment-Resistant Depression
• Point8 Capital to receive equity participation through options

Nexalis Therapeutics Limited (ASX: NX1) has signed a binding letter of intent (LOI) with Point8 Capital Pty Ltd to replace its existing debt funding facility with Linlithgow Family Office Pty Ltd. The new Point8 Facility will provide up to $53 million in non-dilutive funding across three sub-facilities aligned with Nexalis' core clinical programs: IRX-211 for Breakthrough Cancer Pain, IRX-616a for Panic Disorder, and SRX-25 for Treatment-Resistant Depression. The facility includes a 15% per annum interest rate, a general security deed over all assets, and equity participation through the issuance of 49.34 million options to Point8. The new facility is subject to shareholder approval and the execution of finalized transaction documents.

Nexalis secures up to $53 million in funding capacity for its clinical programs.

Nexalis anticipates that the new funding facility will support the advancement of its clinical programs, pending shareholder approval and finalization of transaction documents.